CG Labz
Peptide Library / Growth Hormone / Performance

CJC-1295 + Ipamorelin Blend

GHRH + GHRP Blend

CJC-1295 + Ipamorelin Blend Research Protocol

Complete Research Guide 4 min read2 peer-reviewed references

Quickstart Overview

This blend pairs CJC-1295 (no DAC / Mod GRF 1-29), a GHRH analog, with ipamorelin, a selective ghrelin-receptor agonist. The two act on different pituitary receptors, and together they produce a greater GH pulse than either compound alone — the most-studied secretagogue stack.

Reconstitution
Add 2.0 mL bacteriostatic water to the 10 mg (5+5) vial → 5 mg/mL
Blend
CJC-1295 (no DAC) + Ipamorelin 1:1
Measuring Reference
At 5 mg/mL: 200 mcg total = 0.04 mL = 4 units
Frequency
1–3× daily, fasted
Route (studies)
Subcutaneous
Cycle
8–12 weeks

Scientific Data

Molecular Formula
—
Molecular Weight
—
Sequence
CJC-1295 (no DAC) + Ipamorelin 1:1
Sequence Length
18
CAS
Research compound
Peptide Family
Blend
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.040 mL
Syringe Units
4.0 U
Doses / Vial
50

Units assume a U-100 insulin syringe (100 units = 1 mL). The classic pre-bed GH stack; dose fasted for the strongest pulse.

Frequency: 1–3× daily, fasted

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 12-week protocol at approximately 400 mcg per day.

Peptide (10 mg vials)
Estimate vials from total mass: 400 mcg/day × 84 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model synergistic GHRH + ghrelin GH release.
Schedule
Daily, 8–12 weeks.
Dose Range
100 mcg of each, 1–3×/day.

Dosing Protocol

Start
100 mcg of each, once daily pre-bed
Target
100 mcg each, 1–3× daily
Frequency
Pre-bed primary; fasted AM/post-training optional
Cycle Length
8–12 weeks on, 4 off
Timing
Fasted — carbs/fats blunt the GH pulse
Route
Subcutaneous

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Fasted timing is critical for an effective GH pulse.
  • Ipamorelin's selectivity keeps the combined pulse free of cortisol/prolactin spikes.

How This Works

CJC-1295 stimulates the GHRH receptor (increasing GH synthesis and release) while ipamorelin activates the GHS-R1a ghrelin receptor (amplifying the pulse and suppressing somatostatin). Because the pathways are complementary, co-administration yields a synergistic GH pulse. Ipamorelin's selectivity keeps cortisol and prolactin essentially unchanged, so the combined pulse stays clean.

Potential Benefits & Side Effects

Reported in research
  • Synergistic GH pulse greater than either alone
  • Clean profile — minimal cortisol/prolactin activity
  • Improved sleep, recovery and body composition
  • Convenient single-draw co-administration
Possible considerations
  • Water retention and mild joint stiffness
  • Flushing/head-rush after dosing
  • Transient tingling in extremities
  • Injection-site reactions
  • Increased appetite (mild)

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] European Journal of Endocrinology
    Raun K. et al. Ipamorelin, the first selective GH secretagogue.
    View Source
  2. [2] J Clin Endocrinol Metab
    Teichman S.L. et al. CJC-1295 stimulation of GH and IGF-1.
    View Source